CellCentric is a UK based biotechnology company with offices in Cambridge, Oxford and Manchester (Alderley Park). It has partnered and collaborated with researchers and clinicians across the world, from West Coast USA to Japan. The company is privately held; it’s lead investor is Boston based, Morningside Ventures.

The company’s leadership has deep R&D experience gained in academia, large pharma and biotechs, spanning from basic biological research through to international clinical development programmes.